Mary E. Hanson

1.6k total citations
60 papers, 1.3k citations indexed

About

Mary E. Hanson is a scholar working on Surgery, Economics and Econometrics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Mary E. Hanson has authored 60 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Surgery, 16 papers in Economics and Econometrics and 10 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mary E. Hanson's work include Lipoproteins and Cardiovascular Health (28 papers), Pharmaceutical Economics and Policy (16 papers) and Cancer, Lipids, and Metabolism (10 papers). Mary E. Hanson is often cited by papers focused on Lipoproteins and Cardiovascular Health (28 papers), Pharmaceutical Economics and Policy (16 papers) and Cancer, Lipids, and Metabolism (10 papers). Mary E. Hanson collaborates with scholars based in United States, Canada and Belgium. Mary E. Hanson's co-authors include Andrew M. Tershakovec, Arvind Shah, Jianxin Lin, Robert S. Lowe, Peter P. Tóth, William S. Weintraub, Doralisa Morrone, Daisy Ng‐Mak, Ralph P. Insinga and Harold Bays and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Mary E. Hanson

59 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary E. Hanson United States	20	678	242	228	215	214	60	1.3k
Alex Gold United States	20	487 0.7×	106 0.4×	201 0.9×	148 0.7×	72 0.3×	42	2.0k
José María Mostaza Spain	24	865 1.3×	64 0.3×	270 1.2×	284 1.3×	91 0.4×	138	1.7k
Robert Cramb United Kingdom	22	718 1.1×	52 0.2×	371 1.6×	98 0.5×	123 0.6×	50	1.7k
Francesco Dati Germany	22	888 1.3×	74 0.3×	257 1.1×	68 0.3×	201 0.9×	77	2.3k
Mathieu Kernéis France	26	816 1.2×	134 0.6×	193 0.8×	60 0.3×	66 0.3×	107	2.3k
Amir Kashani United States	17	570 0.8×	40 0.2×	206 0.9×	135 0.6×	77 0.4×	42	1.5k
Craig A. Sponseller United States	15	379 0.6×	137 0.6×	170 0.7×	78 0.4×	98 0.5×	33	750
Wim A. van der Steeg Netherlands	10	789 1.2×	59 0.2×	168 0.7×	67 0.3×	249 1.2×	14	1.3k
Achuta Kumar Guddati United States	18	194 0.3×	106 0.4×	122 0.5×	45 0.2×	105 0.5×	101	1.2k

Countries citing papers authored by Mary E. Hanson

Since Specialization

Citations

This map shows the geographic impact of Mary E. Hanson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Hanson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Hanson more than expected).

Fields of papers citing papers by Mary E. Hanson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary E. Hanson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Hanson. The network helps show where Mary E. Hanson may publish in the future.

Co-authorship network of co-authors of Mary E. Hanson

This figure shows the co-authorship network connecting the top 25 collaborators of Mary E. Hanson. A scholar is included among the top collaborators of Mary E. Hanson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary E. Hanson. Mary E. Hanson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wassil, James, Massimo Sisti, Jeff Fairman, et al.. (2024). A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older. Vaccine. 42(25). 126124–126124. 6 indexed citations

Simon, Jakub K., Stephen B. Kennedy, Barbara E. Mahon, et al.. (2022). Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Vaccine. 40(46). 6599–6606. 11 indexed citations

Basu, Anirban, Vimalanand S. Prabhu, Marcus Dörr, et al.. (2018). Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. Open Forum Infectious Diseases. 5(11). ofy218–ofy218. 6 indexed citations

Oshima, Nobuyuki, et al.. (2015). A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids in Health and Disease. 14(1). 40–40. 17 indexed citations

Ogawa, Yoshiaki, Michinori Ogura, Kensei Tobinai, et al.. (2015). A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology. 103(1). 25–33. 11 indexed citations

Tomassini, Joanne E., J. Lin, Arvind Shah, et al.. (2015). Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis. 240(2). 482–489. 32 indexed citations

Kosoglou, Teddy, Paul Statkevich, Bhavna Kantesaria, et al.. (2014). Vorapaxar, an oral PAR‐1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone. Clinical Pharmacology in Drug Development. 4(1). 56–62. 2 indexed citations

Constance, Christian, Ori Ben‐Yehuda, Nanette K. Wenger, et al.. (2014). Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years. Lipids in Health and Disease. 13(1). 13–13. 22 indexed citations

Rakugi, Hiromi, Takuya Tsuchihashi, Kazuyuki Shimada, et al.. (2014). Efficacy and safety of losartan 100 mg/hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension: two randomized, controlled trials. Hypertension Research. 37(12). 1042–1049. 1 indexed citations

10.

Kaplan, Steven A., Edward A. O’Neill, Robert Lowe, Mary E. Hanson, & Alan G. Meehan. (2013). Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS). The Aging Male. 16(2). 48–51. 15 indexed citations

11.

Yu, Chih‐Chieh, Wen‐Ter Lai, Kuang‐Chung Shih, et al.. (2012). Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Research Notes. 5(1). 251–251. 11 indexed citations

12.

Morrone, Doralisa, William S. Weintraub, Peter P. Tóth, et al.. (2012). Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 223(2). 251–261. 204 indexed citations

13.

Civeira, Fernando, et al.. (2012). Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids in Health and Disease. 11(1). 18–18. 12 indexed citations

14.

Tóth, Peter P., Doralisa Morrone, William S. Weintraub, et al.. (2012). Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks. International Journal of Clinical Practice. 66(8). 800–812. 10 indexed citations

15.

Abramson, Beth L., Pascale Benlian, Mary E. Hanson, et al.. (2011). Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients. Lipids in Health and Disease. 10(1). 146–146. 21 indexed citations

16.

Bays, Harold, Scott Conard, Lawrence A. Leiter, et al.. (2010). Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. Lipids in Health and Disease. 9(1). 136–136. 19 indexed citations

17.

Conard, Scott, Harold Bays, Lawrence A. Leiter, et al.. (2009). Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obesity and Metabolism. 12(3). 210–218. 29 indexed citations

18.

Zieve, Franklin J., Nanette K. Wenger, Ori Ben‐Yehuda, et al.. (2009). Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study). The American Journal of Cardiology. 105(5). 656–663. 39 indexed citations

19.

Leiter, Lawrence A., Harold Bays, Scott Conard, et al.. (2008). Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease. The American Journal of Cardiology. 102(11). 1495–1501. 71 indexed citations

20.

Stevens, P. E., Stephen J. Gwyther, J. E. Boultbee, et al.. (1989). PRACTICAL USE OF DUPLEX DOPPLER ANALYSIS OF THE RENAL VASCULATURE IN CRITICALLY ILL PATIENTS. The Lancet. 333(8632). 240–242. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact